Position in RXRX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$17,302,497
+$8,470,330 QoQ
Shares Held
4,714,577
+63.9% QoQ
Ownership
0.881%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#16
of 344 holders
Holding Since
Jun 2022
9 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in RXRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. RXRX ranks #47 (0.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in RXRX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $17,302,497 | 4,714,577 | Shares | Other | 2026-08-13 | |
| 2026-03-31 | $8,832,167 | 2,876,928 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $926,830 | 226,609 | Shares | Other | 2026-02-13 | |
| 2025-09-30 | $381,903 | 78,259 | Shares | Other | 2025-11-13 | |
| 2025-06-30 | $436,738 | 86,312 | Shares | Other | 2025-08-13 | |
| 2025-03-31 | $1,764,807 | 333,612 | Shares | Other | 2025-05-15 | |
| 2024-03-31 | $3,903,434 | 391,518 | Shares | Other | 2024-05-15 | |
| 2023-03-31 | $3,429,292 | 514,137 | Shares | Other | 2023-05-15 | |
| 2022-06-30 | $869,238 | 106,786 | Shares | Other | 2022-08-15 | |
| No filing history on record for this holder in this stock. | ||||||